New hope for NRAS-Mutant cancers: targeted drug binimetinib under study
NCT ID NCT04439344
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing the drug binimetinib in 53 people whose cancers (excluding melanoma) have a specific genetic change called an NRAS mutation. Binimetinib blocks certain proteins that help these cancer cells grow. The study aims to see if the drug can shrink tumors or stop them from growing. It is part of the larger MATCH program, which matches treatments to genetic changes in a patient's tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Binimetinib (a drug that blocks MEK proteins, which cancer cells with NRAS mutations may need to grow)
- What this could lead to
- If it works, this could provide a treatment option for several types of cancer that share an NRAS mutation, especially when other treatments have failed.
- What could go wrong
- This is a small, early-phase trial (53 people) across many cancer types, so results may not apply broadly. The drug may not shrink tumors or improve survival, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a new PET tracer reveal hidden immune clues in tumors?
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a protein calm the immune System's overreaction to cancer treatment?
- A hug in a blanket: could deep pressure calm cancer infusion anxiety?
- Could a strong social circle turn back the clock for transplant survivors?